TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06546670: A Phase I/II Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 161 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$4,740,960

Rescue Site Savings

+$3,132,420

Unlock Full NCT06546670 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06546670 Rescue Dossier →